213 related articles for article (PubMed ID: 30511350)
1. Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
Awad AG
CNS Drugs; 2019 Jan; 33(1):1-8. PubMed ID: 30511350
[TBL] [Abstract][Full Text] [Related]
2. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
Awad AG; Voruganti LN
CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic dysphoria: revisiting the concept 50 years later.
Awad AG; Voruganti LN
Acta Psychiatr Scand Suppl; 2005; (427):6-13. PubMed ID: 15877718
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic dysphoria: towards a new synthesis.
Voruganti L; Awad AG
Psychopharmacology (Berl); 2004 Jan; 171(2):121-32. PubMed ID: 14647964
[TBL] [Abstract][Full Text] [Related]
5. Subjective experiences on antipsychotic medications: synthesis and conclusions.
Marder SR
Acta Psychiatr Scand Suppl; 2005; (427):43-6. PubMed ID: 15877721
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior.
Awad AG; Voruganti LL
Ther Adv Psychopharmacol; 2015 Jun; 5(3):172-8. PubMed ID: 26199720
[TBL] [Abstract][Full Text] [Related]
7. New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
Awad AG; Voruganti LN
Can J Psychiatry; 2004 May; 49(5):297-302. PubMed ID: 15198465
[TBL] [Abstract][Full Text] [Related]
8. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.
Awad AG; Voruganti LN
CNS Drugs; 2013 Aug; 27(8):625-36. PubMed ID: 23757184
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
10. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
12. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
Lambert M; Schimmelmann BG; Karow A; Naber D
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
[TBL] [Abstract][Full Text] [Related]
13. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
14. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation.
Awad AG; Voruganti LN; Heslegrave RJ
Qual Life Res; 1997 Jan; 6(1):21-6. PubMed ID: 9062438
[TBL] [Abstract][Full Text] [Related]
15. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
Voruganti L; Cortese L; Owyeumi L; Kotteda V; Cernovsky Z; Zirul S; Awad A
Schizophr Res; 2002 Oct; 57(2-3):201-8. PubMed ID: 12223251
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. Pimozide for schizophrenia or related psychoses.
Mothi M; Sampson S
Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
[TBL] [Abstract][Full Text] [Related]
18. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
[TBL] [Abstract][Full Text] [Related]
19. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
